Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer

Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer

Background and ObjectiveGefitinib (GE) is a first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR activating mutations. However, drug resistance limits the clinical efficacy of gefitinib and ulti...

Full description

Bibliographic Details
Main Authors: Hui Chen, Bin Jia, Qiang Zhang, Yu Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Oncology
Subjects:
meclofenamic acid
gefitinib
M6A
non-small cell lung cancer (NSCLC)
drug resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.870636/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.870636/full

Similar Items